BMY vs BVS: fair value comparison
Bristol-Myers Squibb Company and Bioventus Inc. · Updated 2026-10-19
BMY currently screens as overvalued while BVS screens as fairly valued. Within Healthcare, BVS currently sits closer to the top of our ranking by discount to fair value.
| BMY | BVS | |
|---|---|---|
| Verdict | Overvalued | Fairly valued |
| Last price | $59.12 | $13.30 |
| 12-month range | $42.60–$68.09 | $6.53–$15.26 |
| Rank by discount to fair value | #72 of 108 Healthcare | #67 of 108 Healthcare |
| Quality grade | B | B |
| Leverage | High | Moderate |
| Margin trend | Expanding | Stable |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Mixed |
| DCF cross-check | Undervalued | — |
| 52-week position | The upper-middle quarter | The top quarter |
Full single-stock breakdowns: BMY fair value analysis · BVS fair value analysis